Close Menu
Subscribe
Business

Lilly weight-loss pill orforglipron could get FDA approval in 2026, CEO Dave Ricks says

No Comments1 Min Read


Eli Lilly & Co., the Fortune 500 pharmaceutical company that makes the weight-loss injection Zepbound (tirzepatide), has a similar oral drug that could be approved by the FDA in 2026, CEO Dave Ricks told Bloomberg TV in January. 13 of 2025

Eli Lilly & Co., the Fortune 500 pharmaceutical company that makes the weight-loss injection Zepbound (tirzepatide), has a similar oral drug that could be approved by the FDA in 2026, CEO Dave Ricks told Bloomberg TV in January. 13 of 2025

Gam1983/Getty Images



Source link

Share.

Related Posts

Add A Comment
Leave A Reply